Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 6;188(3):623-639.e19.
doi: 10.1016/j.cell.2024.11.038. Epub 2025 Jan 16.

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease

Affiliations

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease

Robert E Handsaker et al. Cell. .

Abstract

In Huntington's disease (HD), striatal projection neurons (SPNs) degenerate during midlife; the core biological question involves how the disease-causing DNA repeat (CAG)n in the huntingtin (HTT) gene leads to neurodegeneration after decades of biological latency. We developed a single-cell method for measuring this repeat's length alongside genome-wide RNA expression. We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect, but SPNs with 150-500+ CAGs lost positive and then negative features of neuronal identity, de-repressed senescence/apoptosis genes, and were lost. Our results suggest that somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously. We conclude that in HD, at any one time, most neurons have an innocuous but unstable HTT gene and that HD pathogenesis is a DNA process for almost all of a neuron's life.

Keywords: CAG; DNA repeats; Huntington’s disease; neurodegeneration; repeat instability; single-nucleus RNA-seq; somatic expansion; striatal projection neurons; triplet repeat disorders.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Patent applications filed by the Broad Institute of MIT and Harvard related to this work include subsets of the authors as inventors. S.A.M. has received compensation for scientific advice to Roche, Pfizer, Biogen, Vertex, and LoQus23 Therapeutics.

References

    1. Huntington’s Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983. - PubMed
    1. Gusella JF, Lee J-M, and MacDonald ME (2021). Huntington’s disease: nearly four decades of human molecular genetics. Hum. Mol. Genet. 30, R254–R263. - PMC - PubMed
    1. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, and International Huntington’s Disease Collaborative Group (2004). A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin. Genet. 65, 267–277. - PubMed
    1. Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, Lowe J, Nair A, O’Callaghan C, Langley C, et al. (2020). Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 19, 502–512. - PMC - PubMed
    1. Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, et al. (2022). A biological classification of Huntington’s disease: the Integrated Staging System. Lancet Neurol. 21, 632–644. - PubMed

LinkOut - more resources